

## Completion of Phase 2a clinical trial in Multiple Sclerosis

Release dated 21 June 2006

CBio has formally completed the first Phase 2a trial in Multiple Sclerosis in 50 patients.

The study was to assess safety, tolerability and pharmacodynamics of Cpn10 administered as multiple intravenous injections. The results in this exploratory study met set objectives. These results along with the results from the recently completed Rheumatoid Arthritis and Plaque Psoriasis studies confirm the high potential of CBio's product XToll™ (Chaperonin 10) in treating autoimmune and chronic inflammatory diseases.

XToll™ has been shown to work by a mode of action different to existing anti-TNF therapies and with a good safety profile.

The clinical trial was carried out in Adelaide (Dr Christopher Kneebone, Department of Neurology, Royal Adelaide Hospital) and the Gold Coast (Dr Simon Broadley, Associate Professor in Neurology, Griffith University).

CBio continues to progress the further commercial development of XToll™.

For further information please contact:

Dr Dennis Feeney  
Chief Scientific Officer  
Ph. 07 38414844  
Fax 07 38418189  
Mobile 0412617311

Dr Wolf Hanisch  
Chief Executive Officer  
Ph. 07 38414844  
Fax 07 38418189  
Mobile 0412339460

**Contact:**

85 Brandl Street  
Brisbane Technology  
Park  
Eight Mile Plains  
Qld 4113 Australia

PO Box 8104  
Sunnybank Plaza  
Sunnybank  
Qld 4109 Australia

Ph: 61 7 3841 4844  
Fax: 61 7 3841 8189

[www.cbio.com.au](http://www.cbio.com.au)

ABN: 76 094 730 417  
ACN: 094 730 417